Exelixis, Inc. (NASDAQ:EXEL – Get Rating) Director Jack L. Wyszomierski sold 15,300 shares of Exelixis stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $16.61, for a total value of $254,133.00. Following the completion of the transaction, the director now directly owns 317,467 shares of the company’s stock, valued at approximately $5,273,126.87. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Exelixis Trading Up 3.9 %
Shares of NASDAQ:EXEL opened at $17.47 on Wednesday. The stock has a 50 day moving average of $17.13 and a 200 day moving average of $16.75. The company has a market cap of $5.66 billion, a PE ratio of 30.65, a price-to-earnings-growth ratio of 0.67 and a beta of 0.69. Exelixis, Inc. has a 12-month low of $14.87 and a 12-month high of $23.40.
Exelixis (NASDAQ:EXEL – Get Rating) last posted its quarterly earnings results on Tuesday, February 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Exelixis had a return on equity of 7.54% and a net margin of 11.31%. The business had revenue of $423.92 million during the quarter, compared to the consensus estimate of $418.71 million. During the same quarter in the previous year, the company earned $0.29 earnings per share. The company’s revenue for the quarter was down 6.0% compared to the same quarter last year. Equities research analysts predict that Exelixis, Inc. will post 0.67 earnings per share for the current fiscal year.
Institutional Trading of Exelixis
Wall Street Analysts Forecast Growth
EXEL has been the subject of a number of recent analyst reports. Truist Financial decreased their target price on Exelixis from $35.00 to $32.00 in a research report on Friday, December 9th. Cowen decreased their target price on Exelixis from $21.00 to $20.00 in a research report on Monday, January 9th. Wells Fargo & Company initiated coverage on Exelixis in a research report on Thursday, March 9th. They issued an “overweight” rating and a $23.00 target price for the company. JMP Securities decreased their target price on Exelixis from $25.00 to $24.00 and set a “market outperform” rating for the company in a research report on Thursday, January 19th. Finally, Piper Sandler reissued an “overweight” rating and issued a $32.00 target price on shares of Exelixis in a research report on Wednesday, February 8th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.00.
Exelixis, Inc operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
- Get a free copy of the StockNews.com research report on Exelixis (EXEL)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.